Clinical trialsCompany release

MAIA reports 88% disease control for ateganosine-cemiplimab in third-line NSCLC

🇺🇸 MAIA Biotechnology, Inc. (MAIA) · Tue 17 Nov 2026

Updated interim Phase 2 THIO-101 Part C data show disease control in 38 of 43 evaluable patients, as the company eyes a possible accelerated approval filing.

MAIA Biotechnology has released updated interim results from Part C of its Phase 2 THIO-101 trial, which tests ateganosine followed by cemiplimab (Libtayo) in patients with advanced non-small cell lung cancer (NSCLC) in the third-line setting. The announcement is dated 17 November 2026.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): MAIA Biotechnology, Inc. ↗

Article written by VigiEye from the official source (MAIA Biotechnology, Inc.). Claims are the company's own. AI-assisted; check the source before acting.